For the EMA, it was necessary to develop an independent guideline on the topic as – despite the existence of harmonised ICH documents – specific aspects of the validation of biotechnology-derived products have been missing. A draft is now available.
EMA publishes Guideline Draft on Validation of biotechnology-derived Products
Reblogged this on New Drug Approvals.
Reblogged this on MedCheminAustralia.